Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 4, 2012

View Archived Issues

New B-raf inhibitors presented by Array BioPharma and Genentech

Ablynx and Merck & Co. enter collaboration for Nanobody candidates

Intravenous dosing of GSK-322 investigated in healthy subjects

FDA approves extended-release liquid methylphenidate for ADHD

Phase III Abraxane trial meets primary endpoint

Astex begins phase II trial of SGI-110 in platinum-resistant recurrent ovarian cancer

PolyMedix presents new antimicrobials against biowarfare pathogens

Ipragliflozin has beneficial effects in Japanese patients with type 2 diabetes

Eravacycline compared to ertapenem in patients with intra-abdominal infections

Spanish researchers disclose new immunogenic compositions

Sanofi patents new 11-beta-HSD1 inhibitors

Merck Serono creates spin-off company to focus on neurodegenerative diseases

Ipsen provides update on hemophilia product agreement with Inspiration Biopharmaceuticals

Thrombolytic Science International begins phase I study of TS-01

Mallinckrodt completes acquisition

Athersys updates on MultiStem adult stem cell phase II study

Curis begins phase I trial of oral formulation of CUDC-101 in solid tumors

First data on once-weekly DPP IV inhibitor MK-3102 reported

Development and commercialization agreement reached for velusetrag for gastroparesis

Servier and EOS conclude collaboration and license agreement for E-3810

CBL-0102 receives U.S. orphan drug designation for hepatocellular carcinoma

Sanofi and Bristol-Myers Squibb restructure alliance

Omeros completes enrollment in second phase III OMS-302 trial

Phase Ib trial of RG-3039 commences

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...